Galena Biopharma, Inc. (NASDAQ:GALE) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

Exhibit Index

Galena Biopharma, Inc. Exhibit
EX-99.1 2 d468049dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Galena Biopharma Announces Completion of Enrollment in Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab Interim efficacy analysis expected in Q1,…
To view the full exhibit click here

About Galena Biopharma, Inc. (NASDAQ:GALE)

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.